Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes

详细信息    查看全文

• 作者：Xueying Tan^a ; ^{tanxueying@163.com" class="auth_mail" title="E-mail the corresponding author} ; Jingbo Hu^b ; ^{hujiaabo@163.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Glyxambi® ; Empagliflozin ; Linagliptin ; Type 2 diabetes
• 刊名：Annales d'Endocrinologie
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：77
• 期：5
• 页码：557-562
• 全文大小：493 K

文摘

Glyxambi^® (empagliflozin/linagliptin) is a fixed-dose, once-daily tablet combining a sodium glucose co-transporter-2 (SGLT2) inhibitor with a dipeptidyl peptidase-4 (DPP-4) inhibitor. Glyxambi^® is served as an adjuvant to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments. Glyxambi^® combines 10 mg or 25 mg empagliflozin with 5 mg linagliptin, with different, complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes. Empagliflozin removes glucose through the urine by blocking blood glucose re-absorption in the kidney, and linagliptin exerts glucose-lowering activity by increasing hormones that stimulate the pancreas to produce more insulin and decreasing the levels of glucagon in the circulation. In addition, this combination therapy modestly reduces body weight and blood pressure without significant safety issues.